The Core Unit for Molecular Tumor Diagnostics (CMTD) is a research facility for the molecular characterization of sporadic and hereditary tumors based on next generation sequencing (NSG) techniques, bioinformatic analysis pipelines and interpretation of the results by experienced molecular pathologists and human geneticists. It is an essential and fundamental interface in the area of translational cancer research and clinical studies. The aim of the CMTD is the fast translation of novel molecular markers into clinical application by making indication-specific multi gene panels available.
Core Unit for Molecular Tumor Diagnostics
For a new project please fill in the CMTD request form and send them to: cmtd-service(at)nct-dresden.de
Please keep the project title short and unique for your project. As project description 2-3 short sentences about your project are sufficient. All other fields are optional, but will help us and you for a better planning of your project.
Please contact us for consultation prior to sequencing projects. This will allow us to provide initial support in study design and therefore optimize the performance of the NGS experiments.
We offer high-throughput sequencing services, consultation and expert assistance in planning, sample preparation and method development.
Here are a few examples of what we offer:
- Illumina TruSight Oncology
- Illumina TruSight Tumor 15 Panel
- Illumina TruSight Tumor 170 Panel
- Qiagen Human Comprehensive Cancer Panel
DNA Sequencing_Custom Panel
Additional methods and support
RNA Sequencing_Whole Transcriptome
Prof. Dr. med. Gustavo Baretton
Director of the Institute for Pathology
Co-Director Core Unit for Molecular Tumor Diagnostics
Tel.: +49 (0) 351 458 3000
Prof. Dr. med. Daniela Aust
Institute for Pathology
Tel.: +49 (0)351 458 3004
Dr. rer. nat. Doreen William
Head of Molecular Genetic Research of the Institute for Clinical Genetics
Tel.: +49 (0)351 458 13914
Dr. rer. nat. Stephan Drukewitz
Dr. rer. nat. Anja Kögler
Tel.: +49 (0)351 458 11745